Datroway® Approved for Metastatic Breast Cancer
Datopotamab deruxtecan (DATROWAY), a TROP2-directed antibody-drug conjugate (ADC), has received US approval for treating adults with unresectable or metastatic...
FDA Accepts Arrowhead’s New Drug Application for Plozasiran Treatment
Arrowhead Pharmaceuticals announced that the FDA accepted its New Drug Application (NDA) for plozasiran, a treatment for the rare...
Zai Lab’s KarXT for Schizophrenia Treatment Accepted by FDA
Zai Lab’s New Drug Application (NDA) for KarXT, a schizophrenia treatment for adults, has been accepted by China’s National...
Acalabrutinib Plus Chemoimmunotherapy Approved for Mantle Cell Lymphoma
The FDA has granted full approval to AstraZeneca’s CALQUENCE (acalabrutinib) combined with bendamustine and rituximab for first-line treatment of...
Enigma Biomedical & Neuraly Announce Research & Commercialization Deal
Neuraly Inc., a subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. signed a research license and commercialization...
Nasdaq Lists Disc Medicine Grant Under Rule 5635(c)(4)
Disc Medicine granted a new employee an equity award consisting of a stock option to purchase 35,000 shares and...
Abbott’s Roadmap to Diversifying Clinical Trials
In this interview, Jennifer Jones-McMeans, Ph.D., co-leader of Abbott’s Diversity in Research Office and divisional vice president of global...
Shionogi’s S-892216: Breakthrough COVID-19 Antiviral for At-Risk Groups
Shionogi Inc. secured a $375 million agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop S-892216,...
Silexion’s SIL-204 Shows Synergy Against KRAS-Driven Cancers
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company, has released promising preclinical data for SIL-204, its next-generation RNA interference...
Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496
Rubedo Life Sciences announced clinical development plans for RLS-1496, a first-in-class GPX4 modulator targeting aging cells, at the 12th...